Cañas-Alvaro, RodrigoLalaguna, LauraRubio, BlancaAusiello, AntonellaLópez-Olañeta, MarinaSerrano-Blanco, Rocío FOchoa, Juan Pablode la Pompa, Jose LuisChavez, AlejandroGarcía-Pavía, PabloLara-Pezzi, Enrique2025-12-102025-12-102025-11-14Eur Heart J. 2025 Nov 14;46(43):4610-4613.https://hdl.handle.net/20.500.12105/27007This project was funded by the Pathfinder Cardiogenomics programme of the European Innovation Council of the European Union (DCM-NEXT project; project number: 101115416) to E.L.-P. and P.G.-P. and grants PID2021-124629OB-I00, TED2021-129774B-C22, and PLEC2022-009235 funded by the Ministry of Science and Innovation (MCIN/AEI/10.13039/501100011033), by the European Union’s NextGenerationEU/PRTR (‘Plan de Recuperación, Transformación y Resiliencia de España’) and by FEDER to E.L.-P. and grants PID2022-136942OB-I00, CB16/11/00399 (CIBER CV) from MICIU/AEI/10.13039/501100011033, and La Caixa Research Health Foundation (HR23-00084) to J.L.d.l.P. The CNIC is supported by the Instituto de Salud Carlos III (ISCIII), the Ministerio de Ciencia, Innovación y Universidades (MICIU), and the Pro CNIC Foundation and is a Severo Ochoa Center of Excellence (grant CEX2020-001041-S funded by MICIU/AEI/10.13039/501100011033). A.C. was supported by NIH Grant DP2NS131566-01 and a Career Award for Medical Scientists from the Burroughs Wellcome Foundation.engVoRhttp://creativecommons.org/licenses/by-nc-nd/4.0/CRISPR activationCardiomyopathyDilated cardiomyopathyFLNC truncating variantsGene therapyNon-dilated left ventricular cardiomyopathyAttribution-NonCommercial-NoDerivatives 4.0 International4088606046434610-4613https://doi.org/10.1093/eurheartj/ehaf703open access